胶质母细胞瘤中EGFRvⅢ及其靶向治疗研究进展  

Research Progress of EGFRvⅢand Its Targeted Therapy in Glioblastoma

作　　者：马亚光 龙宇[1] 胡力[1] 沈红[1] 刘利[1] 林志国[1] MA Yaguang;LONG Yu;HU Li;SHEN Hong;LIU Li;LIN Zhiguo(Department Four of Neurosurgery,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院神经外科四,哈尔滨150001

出　　处：《医学综述》2021年第24期4816-4820,共5页Medical Recapitulate

基　　金：国家自然科学基金(81772678,81802755)。

摘　　要：胶质母细胞瘤(GBM)是中枢神经系统最常见的恶性肿瘤,其治疗效果差,具有较高的复发性,严重影响人类健康。由于分子生物学的进展,GBM的形成机制不断得到完善,但部分靶向药物穿透血脑屏障相对较少,导致相关化疗药物治疗效果不明显。而表皮生长因子受体Ⅲ型突变体(EGFRvⅢ)在胶质瘤形成与发展中起重要作用,其通过建立相关信号网络通路调控机制能够增强GBM的细胞增殖和侵袭能力,从而进一步提高GBM的致瘤潜能,全面了解有关EGFRvⅢ参与致瘤性潜能,能够开发出相关靶向治疗药物。因此,需开展针对EGFRvⅢ参与复杂网络信号通路的研究,并进一步探讨靶向性潜在治疗方案。Glioblastoma(GBM)is the most common malignant tumor of the central nervous system.It has poor therapeutic effect and high recurrence,which seriously affects human health.Due to the progress of molecular biology,the formation mechanism of GBM has been constantly improved,but relatively few targeted drugs can penetrate the blood brain barrier,resulting in the unsatisfactory effect of relevant chemotherapeutic drugs.Epidermal growth factor receptor variantⅢ(EGFRvⅢ)plays an important role in the formation and development of glioma,which can enhance the cell proliferation and invasion ability of GBM by establishing relevant signal network pathway regulation mechanism,thus further improving GBM tumorigenetic potential.A comprehensive understanding of the tumogenic potential of EGFRvⅢwill enable the develo-pment of the associated targeted drugs.Therefore,it is necessary to study the involvement of EGFRvⅢin complex network signaling pathways and further explore the potential targeted therapies.

关 键 词：胶质母细胞瘤 表皮生长因子受体Ⅲ型突变体 信号通路 靶向治疗 

分 类 号：R739.4[医药卫生—肿瘤]